Gavitt Alida Woodard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gavitt Alida Woodard has a total of 152 co-authors. Here are the top co-authors by number of shared publications:
David M. Jablons
Department of Surgery, University of California San Francisco, San Francisco, California
6 shared publicationsSanja Dacic
6 shared publicationsDaniel J. Boffa
5 shared publicationsJustin D. Blasberg
5 shared publicationsJustin M. Bader
5 shared publicationsWilliam de Santis
5 shared publications
Latest Publications
- 2 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- p. OF1-OF10
Phenotypic and Functional Characterization of Tumor-Reactive T Cells in Malignant Pleural Effusions
Adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) is effective for treating advanced melanoma but requires surgical tumor resection. Malignant pleural effusions (MPE) may provide a more accessible source of tumor-reactive T cells. Synchronously collected MPE, lung metastasis, and blood from a patient with metastatic melanoma were analyzed using high-dimensional flow cytometry and single-cell RNA/T-cell receptor (TCR) sequencing. TCR reactivity to autologous tumor was tested in vitro. The proliferative and cytotoxic capacity of ex vivo expanded T cells was assessed in vitro. MPE contained a higher fraction of CD3+ T cells compared with tumor and was enriched for effector CD8+ T cells and effector memory CD4+ T cells. Compared with TIL, MPE T cells exhibited lower features of T-cell exhaustion and higher cytotoxicity signatures. The clonal repertoire of MPE and tumor highly overlapped, including 62.2% of predicted neoantigen-specific TCR (NeoTCR) clonotypes. MHC class I–restricted reactivity was functionally confirmed in two of four selected NeoTCR clonotypes. MPE T cells demonstrated higher proliferative capacity under high-dose IL2 expansion relative to TIL and achieved comparable MHC class I–dependent tumor killing. Overall, MPE contains polyclonal, tumor-reactive T cells with favorable functional features, supporting MPE as an accessible source for TIL therapy.
- 2 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- p. OF1-OF10
Phenotypic and Functional Characterization of Tumor-Reactive T Cells in Malignant Pleural Effusions
Adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) is effective for treating advanced melanoma but requires surgical tumor resection. Malignant pleural effusions (MPE) may provide a more accessible source of tumor-reactive T cells. Synchronously collected MPE, lung metastasis, and blood from a patient with metastatic melanoma were analyzed using high-dimensional flow cytometry and single-cell RNA/T-cell receptor (TCR) sequencing. TCR reactivity to autologous tumor was tested in vitro. The proliferative and cytotoxic capacity of ex vivo expanded T cells was assessed in vitro. MPE contained a higher fraction of CD3+ T cells compared with tumor and was enriched for effector CD8+ T cells and effector memory CD4+ T cells. Compared with TIL, MPE T cells exhibited lower features of T-cell exhaustion and higher cytotoxicity signatures. The clonal repertoire of MPE and tumor highly overlapped, including 62.2% of predicted neoantigen-specific TCR (NeoTCR) clonotypes. MHC class I–restricted reactivity was functionally confirmed in two of four selected NeoTCR clonotypes. MPE T cells demonstrated higher proliferative capacity under high-dose IL2 expansion relative to TIL and achieved comparable MHC class I–dependent tumor killing. Overall, MPE contains polyclonal, tumor-reactive T cells with favorable functional features, supporting MPE as an accessible source for TIL therapy.
- Open Access
- 31 October 2026
- Published by Elsevier in JTO Clinical and Research Reports
Real-World Survival After Neoadjuvant Chemoimmunotherapy for Resectable Non-Small Cell Lung Cancer
- 31 October 2026
- Published by Elsevier in JTO Clinical and Research Reports
Open AccessReal-World Survival After Neoadjuvant Chemoimmunotherapy for Resectable Non-Small Cell Lung Cancer
- 1 July 2026
- Published by Wolters Kluwer Health in The Cancer Journal
- Vol. 32 (4)
Early-Stage NSCLC: Novel Surgical Techniques and Neoadjuvant, Adjuvant, and Perioperative Therapies
Neoadjuvant and perioperative chemoimmunotherapy has transformed the treatment of tumors >4 cm or node-positive disease (stage II to IIIA, AJCC 8th edition) in non-small cell lung cancer (NSCLC). Compared with neoadjuvant chemotherapy alone, the addition of neoadjuvant immunotherapy to chemotherapy before resection has demonstrated improved pathologic complete response rate, event-free survival, and overall survival in stage II to IIIA NSCLC. The benefit observed with pathologic response after neoadjuvant therapy expands to include patients with stage II to IIIB NSCLC with sensitizing EGFR mutations with neoadjuvant osimertinib and is being evaluated with targeted therapies in additional actionable genomic drivers. Predictive biomarkers for pathologic response after neoadjuvant or perioperative therapies and biomarkers for disease recurrence, including evaluation of minimal residual disease through liquid biopsies, are under investigation to identify NSCLC patients who may have long-term survival with neoadjuvant or perioperative treatment. This chapter summarizes the current clinical landscape of neoadjuvant, perioperative, and adjuvant therapies and updates on surgical techniques for early-stage NSCLC.
- 1 July 2026
- Published by Wolters Kluwer Health in The Cancer Journal
- Vol. 32 (4)
Early-Stage NSCLC: Novel Surgical Techniques and Neoadjuvant, Adjuvant, and Perioperative Therapies
Neoadjuvant and perioperative chemoimmunotherapy has transformed the treatment of tumors >4 cm or node-positive disease (stage II to IIIA, AJCC 8th edition) in non-small cell lung cancer (NSCLC). Compared with neoadjuvant chemotherapy alone, the addition of neoadjuvant immunotherapy to chemotherapy before resection has demonstrated improved pathologic complete response rate, event-free survival, and overall survival in stage II to IIIA NSCLC. The benefit observed with pathologic response after neoadjuvant therapy expands to include patients with stage II to IIIB NSCLC with sensitizing EGFR mutations with neoadjuvant osimertinib and is being evaluated with targeted therapies in additional actionable genomic drivers. Predictive biomarkers for pathologic response after neoadjuvant or perioperative therapies and biomarkers for disease recurrence, including evaluation of minimal residual disease through liquid biopsies, are under investigation to identify NSCLC patients who may have long-term survival with neoadjuvant or perioperative treatment. This chapter summarizes the current clinical landscape of neoadjuvant, perioperative, and adjuvant therapies and updates on surgical techniques for early-stage NSCLC.
- Open Access
- 1 June 2026
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 18 (6) , 664
Increased rates of surgical resection of early-stage small cell lung cancer in a single-institution cohort
Increasing chest imaging utilization, including for screening, identifies more non-small cell lung cancer (NSCLC) at earlier stages. We suspected that a parallel increase in early detection and resection of small cell lung cancer (SCLC) was also occurring. We therefore reviewed our institutional experience to explore trends in surgically resected SCLC frequency and outcomes. A single-institution, retrospective review was performed of all SCLC cases resected between 2000-2022. We evaluated demographics, oncologic characteristics, overall survival (OS), and disease-free survival (DFS). Among 30 patients with resected SCLC, the majority underwent lobectomy (73%) and only 37% were known to have SCLC preoperatively. The frequency of resections increased over time with almost half (47%) occurring in the last four study years (2019-2022). This increase in SCLC resections coincided with increasing lung cancer screening (LCS) volume, with no change in thoracic surgical case volume. The 2019-2022 cohort was predominantly clinical stage I (86%) compared to 56% pre-2019 (I vs. II-IV, P=0.08), and also trended toward more screen-detected (43% vs. 13%, P=0.08) patients. Subgroup analysis showed encouraging OS outcomes following surgical resection for clinical and pathological stage I patients. There was a trend toward better OS among screen-detected patients (73% vs. 34%, log-rank P=0.07) that was significant in DFS (75% vs. 26%, P=0.02). The number of surgically resected SCLC patients at our institution has increased in recent years, as has the proportion of screen-detected and clinical stage I cases, alongside rising LCS volume. This may be an early signal of a broader trend toward increasing diagnosis of limited stage SCLC eligible for resection.
- 1 June 2026
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 18 (6) , 664
Open AccessIncreased rates of surgical resection of early-stage small cell lung cancer in a single-institution cohort
Increasing chest imaging utilization, including for screening, identifies more non-small cell lung cancer (NSCLC) at earlier stages. We suspected that a parallel increase in early detection and resection of small cell lung cancer (SCLC) was also occurring. We therefore reviewed our institutional experience to explore trends in surgically resected SCLC frequency and outcomes. A single-institution, retrospective review was performed of all SCLC cases resected between 2000-2022. We evaluated demographics, oncologic characteristics, overall survival (OS), and disease-free survival (DFS). Among 30 patients with resected SCLC, the majority underwent lobectomy (73%) and only 37% were known to have SCLC preoperatively. The frequency of resections increased over time with almost half (47%) occurring in the last four study years (2019-2022). This increase in SCLC resections coincided with increasing lung cancer screening (LCS) volume, with no change in thoracic surgical case volume. The 2019-2022 cohort was predominantly clinical stage I (86%) compared to 56% pre-2019 (I vs. II-IV, P=0.08), and also trended toward more screen-detected (43% vs. 13%, P=0.08) patients. Subgroup analysis showed encouraging OS outcomes following surgical resection for clinical and pathological stage I patients. There was a trend toward better OS among screen-detected patients (73% vs. 34%, log-rank P=0.07) that was significant in DFS (75% vs. 26%, P=0.02). The number of surgically resected SCLC patients at our institution has increased in recent years, as has the proportion of screen-detected and clinical stage I cases, alongside rising LCS volume. This may be an early signal of a broader trend toward increasing diagnosis of limited stage SCLC eligible for resection.
- Open Access
- 4 May 2026
- Published by Elsevier in JTCVS Open
- Vol. 32
Radiographic tumor regression as a predictor for pathologic response after neoadjuvant therapy for non–small cell lung cancer
- 4 May 2026
- Published by Elsevier in JTCVS Open
- Vol. 32
Open AccessRadiographic tumor regression as a predictor for pathologic response after neoadjuvant therapy for non–small cell lung cancer
- Open Access
- 1 May 2026
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 15 (5) , 131
CEACAM5 as a biomarker of semi-solid, lepidic lung adenocarcinoma
Background: Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) is a cell adhesion molecule implicated in tumor cell migration, invasion, and resistance to apoptosis. Its role as a circulating biomarker in the form of carcinoembryonic antigen (CEA) is well-established in gastrointestinal malignancies. CEACAM5 is also overexpressed in approximately 25% of non-small cell lung cancer (NSCLC), particularly lung adenocarcinoma, yet its role as a biomarker and therapeutic target remains unclear. We previously demonstrated elevated CEACAM5 RNA expression in lepidic adenocarcinomas that appear radiographically as ground-glass opacities (GGOs) and semi-solid lung cancer. In this study, using a separate patient cohort, we assess CEACAM5 protein expression as a potential biomarker in GGO and semi-solid NSCLC. Methods: CEACAM5 immunohistochemistry (IHC) was performed in a Clinical Laboratory Improvement Amendments (CLIA) certified setting on surgically resected NSCLC. Slides underwent expert thoracic pathologist review and quantification of CEACAM5 expression with standardized H-score. Expression was compared between tumors which were radiographically subsolid, ground-glass, with pathologic lepidic adenocarcinoma (GGO) (n=36) versus solid NSCLC tumors (n=98), and sub-group comparisons were performed based on patient and tumor characteristics. Specimens underwent multiplex immunofluorescence to characterize the immune microenvironment and quantify CD8+ T cell and CD20+ B cell infiltration. Results: Lepidic adenocarcinoma GGOs exhibited higher CEACAM5 expression than solid NSCLC (H-score: 53 vs. 27, P vs. 35, P=0.009), squamous cell carcinoma (n=20, H-score: 53 vs. 4.6, P=0.003), and large cell carcinoma (n=10, H-score: 53 vs. 12, P=0.02). Among the GGO cohort, specimens with CEACAM5 H-score 100 exhibited a higher density of PanCK+ tumor cells (5.5% vs. 2.2%, P=0.02). Among the adenocarcinoma cohort, patients with higher stage adenocarcinoma (stage II–IV) had higher CEACAM5 H-scores than patients with stage I adenocarcinoma although not statistically significant (H-score: 50 vs. 28, P=0.09). The GGO specimens with the highest CEACAM5 H-scores (≥100, n=5) had a clinical history of radiographic evolution, and developing a new radiographic solid component prior to surgical resection, compared to GGO with lower CEACAM5 H-scores (Conclusions: Our findings demonstrate that CEACAM5 is significantly overexpressed in lepidic adenocarcinoma GGO compared to other forms of solid NSCLC, suggesting its potential utility as a diagnostic biomarker for this subtype of NSCLC. Future studies should explore the clinical utility of CEACAM5-targeted strategies for early detection of invasive lung cancer and lung nodule risk stratification.
- 1 May 2026
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 15 (5) , 131
Open AccessCEACAM5 as a biomarker of semi-solid, lepidic lung adenocarcinoma
Background: Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) is a cell adhesion molecule implicated in tumor cell migration, invasion, and resistance to apoptosis. Its role as a circulating biomarker in the form of carcinoembryonic antigen (CEA) is well-established in gastrointestinal malignancies. CEACAM5 is also overexpressed in approximately 25% of non-small cell lung cancer (NSCLC), particularly lung adenocarcinoma, yet its role as a biomarker and therapeutic target remains unclear. We previously demonstrated elevated CEACAM5 RNA expression in lepidic adenocarcinomas that appear radiographically as ground-glass opacities (GGOs) and semi-solid lung cancer. In this study, using a separate patient cohort, we assess CEACAM5 protein expression as a potential biomarker in GGO and semi-solid NSCLC. Methods: CEACAM5 immunohistochemistry (IHC) was performed in a Clinical Laboratory Improvement Amendments (CLIA) certified setting on surgically resected NSCLC. Slides underwent expert thoracic pathologist review and quantification of CEACAM5 expression with standardized H-score. Expression was compared between tumors which were radiographically subsolid, ground-glass, with pathologic lepidic adenocarcinoma (GGO) (n=36) versus solid NSCLC tumors (n=98), and sub-group comparisons were performed based on patient and tumor characteristics. Specimens underwent multiplex immunofluorescence to characterize the immune microenvironment and quantify CD8+ T cell and CD20+ B cell infiltration. Results: Lepidic adenocarcinoma GGOs exhibited higher CEACAM5 expression than solid NSCLC (H-score: 53 vs. 27, P vs. 35, P=0.009), squamous cell carcinoma (n=20, H-score: 53 vs. 4.6, P=0.003), and large cell carcinoma (n=10, H-score: 53 vs. 12, P=0.02). Among the GGO cohort, specimens with CEACAM5 H-score 100 exhibited a higher density of PanCK+ tumor cells (5.5% vs. 2.2%, P=0.02). Among the adenocarcinoma cohort, patients with higher stage adenocarcinoma (stage II–IV) had higher CEACAM5 H-scores than patients with stage I adenocarcinoma although not statistically significant (H-score: 50 vs. 28, P=0.09). The GGO specimens with the highest CEACAM5 H-scores (≥100, n=5) had a clinical history of radiographic evolution, and developing a new radiographic solid component prior to surgical resection, compared to GGO with lower CEACAM5 H-scores (Conclusions: Our findings demonstrate that CEACAM5 is significantly overexpressed in lepidic adenocarcinoma GGO compared to other forms of solid NSCLC, suggesting its potential utility as a diagnostic biomarker for this subtype of NSCLC. Future studies should explore the clinical utility of CEACAM5-targeted strategies for early detection of invasive lung cancer and lung nodule risk stratification.
- 10 February 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (5) , 425-426
Is Major Pathologic Response the Best Surrogate End Point for Neoadjuvant Trials?
- 10 February 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (5) , 425-426
Is Major Pathologic Response the Best Surrogate End Point for Neoadjuvant Trials?
- 3 December 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (827) , eadr2277
Dysregulated alveolar type 2 epithelial cell proteostasis promotes fibrogenic macrophage migration inhibitory factor–CD74 signaling
Aberrant proteostasis in alveolar type 2 epithelial cells (AEC2s) contributes to idiopathic pulmonary fibrosis (IPF), but the role of the ubiquitin-proteasome system (UPS) is unclear. Here, we show that UPS disruption in AEC2s amplifies profibrotic signaling to macrophages through macrophage migration inhibitory factor (MIF) family proteins in several models. Modeling UPS disruption with an AEC2-specific cullin 3 ( Cul3 ) deletion produced spontaneous fibrosis in a physiological aging mouse model and exacerbated fibrosis in the bleomycin-induced lung injury model. This was accompanied by expansion of transitional epithelial states and increased MIF and MIF-2 in lung tissue and bronchoalveolar lavage fluid (BALF) in the model. Global or conditional AEC2-specific deletions of Mif or Mif-2 attenuated fibrosis in the bleomycin-treated mouse model, as did conditional deletions of Cd74 , the cognate receptor for MIF and MIF-2, in C-X3-C motif chemokine receptor 1 ( Cx3cr1 )–expressing and platelet factor 4 ( Pf4 )–expressing cells. Pharmacological inhibition of MIF attenuated fibrosis in bleomycin-treated and transforming growth factor–β1 ( TGFB1 ) transgenic mouse models and in ex vivo human precision-cut lung slices treated with fibrotic cocktail. In study participants with IPF, BALF MIF was elevated compared with that in study participants without IPF. In participants with IPF, BALF MIF greater than 4000 picograms per milliliter was associated with increased mortality compared with participants with IPF with lower MIF. Together, these findings define a UPS-sensitive epithelial-macrophage signaling connection and identify MIF-CD74 cross-talk as a potential therapeutic target in fibrotic lung disease.
- 3 December 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (827) , eadr2277
Dysregulated alveolar type 2 epithelial cell proteostasis promotes fibrogenic macrophage migration inhibitory factor–CD74 signaling
Aberrant proteostasis in alveolar type 2 epithelial cells (AEC2s) contributes to idiopathic pulmonary fibrosis (IPF), but the role of the ubiquitin-proteasome system (UPS) is unclear. Here, we show that UPS disruption in AEC2s amplifies profibrotic signaling to macrophages through macrophage migration inhibitory factor (MIF) family proteins in several models. Modeling UPS disruption with an AEC2-specific cullin 3 ( Cul3 ) deletion produced spontaneous fibrosis in a physiological aging mouse model and exacerbated fibrosis in the bleomycin-induced lung injury model. This was accompanied by expansion of transitional epithelial states and increased MIF and MIF-2 in lung tissue and bronchoalveolar lavage fluid (BALF) in the model. Global or conditional AEC2-specific deletions of Mif or Mif-2 attenuated fibrosis in the bleomycin-treated mouse model, as did conditional deletions of Cd74 , the cognate receptor for MIF and MIF-2, in C-X3-C motif chemokine receptor 1 ( Cx3cr1 )–expressing and platelet factor 4 ( Pf4 )–expressing cells. Pharmacological inhibition of MIF attenuated fibrosis in bleomycin-treated and transforming growth factor–β1 ( TGFB1 ) transgenic mouse models and in ex vivo human precision-cut lung slices treated with fibrotic cocktail. In study participants with IPF, BALF MIF was elevated compared with that in study participants without IPF. In participants with IPF, BALF MIF greater than 4000 picograms per milliliter was associated with increased mortality compared with participants with IPF with lower MIF. Together, these findings define a UPS-sensitive epithelial-macrophage signaling connection and identify MIF-CD74 cross-talk as a potential therapeutic target in fibrotic lung disease.
- 15 October 2025
- Published by Elsevier in Thoracic Surgery Clinics
- Vol. 36 (1) , 25-40
Neoadjuvant Tyrosine Kinase Inhibitors
- 15 October 2025
- Published by Elsevier in Thoracic Surgery Clinics
- Vol. 36 (1) , 25-40
Neoadjuvant Tyrosine Kinase Inhibitors